Capital One National Association lowered its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 0.4% during the second quarter, Holdings Channel reports. The institutional investor owned 5,762 shares of the biotechnology company’s stock after selling 24 shares during the period. Capital One National Association’s holdings in Anika Therapeutics were worth $284,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Great West Life Assurance Co. Can increased its position in Anika Therapeutics by 10.3% in the first quarter. Great West Life Assurance Co. Can now owns 21,220 shares of the biotechnology company’s stock worth $921,000 after buying an additional 1,974 shares in the last quarter. Geneva Advisors LLC bought a new stake in shares of Anika Therapeutics during the first quarter worth about $802,000. Wells Fargo & Company MN increased its stake in shares of Anika Therapeutics by 891.4% in the first quarter. Wells Fargo & Company MN now owns 166,674 shares of the biotechnology company’s stock worth $7,240,000 after buying an additional 149,862 shares in the last quarter. HealthInvest Partners AB increased its stake in shares of Anika Therapeutics by 3.2% in the first quarter. HealthInvest Partners AB now owns 181,573 shares of the biotechnology company’s stock worth $7,888,000 after buying an additional 5,606 shares in the last quarter. Finally, Fisher Asset Management LLC increased its stake in shares of Anika Therapeutics by 18.4% in the first quarter. Fisher Asset Management LLC now owns 70,153 shares of the biotechnology company’s stock worth $3,047,000 after buying an additional 10,919 shares in the last quarter. Hedge funds and other institutional investors own 80.90% of the company’s stock.
Shares of Anika Therapeutics Inc. (NASDAQ ANIK) opened at 46.12 on Monday. The company has a 50-day moving average price of $47.03 and a 200-day moving average price of $47.10. The company has a market capitalization of $675.84 million, a P/E ratio of 22.26 and a beta of 1.68. Anika Therapeutics Inc. has a 12 month low of $41.38 and a 12 month high of $53.50.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported $0.37 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.38 by $0.01. The firm had revenue of $23.39 million for the quarter, compared to analysts’ expectations of $23.89 million. Anika Therapeutics had a return on equity of 14.29% and a net margin of 29.81%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.45 earnings per share. On average, analysts forecast that Anika Therapeutics Inc. will post $1.91 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.wkrb13.com/markets/2303103/capital-one-national-association-sells-24-shares-of-anika-therapeutics-inc-nasdaqanik.html.
Separately, Zacks Investment Research downgraded Anika Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 8th.
In other Anika Therapeutics news, CEO Charles H. Sherwood sold 14,201 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total value of $710,476.03. Following the completion of the sale, the chief executive officer now directly owns 246,740 shares in the company, valued at approximately $12,344,402.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jeffery S. Thompson sold 10,725 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $47.39, for a total value of $508,257.75. Following the completion of the sale, the director now owns 15,845 shares of the company’s stock, valued at $750,894.55. The disclosure for this sale can be found here. 6.57% of the stock is owned by corporate insiders.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2303103/capital-one-national-association-sells-24-shares-of-anika-therapeutics-inc-nasdaqanik.html
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.